Clinical Trials

1,207 enrolled 15 charts 2 FDA

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 2 FDA

Prostatic Neoplasms

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 3 FDA

Smoldering Multiple Myeloma

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03390504 2026-04-13

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Prostatic Neoplasms, Castration-Resistant

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

994 enrolled 11 charts 2 FDA

Hodgkin Disease

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 3 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05388669 2026-04-13

PALOMA-3

418 enrolled 16 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04099251 2026-04-09

CheckMate76K

790 enrolled 18 charts 2 FDA

Dermatologic

Melanoma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 3 FDA

Multiple Myeloma

NCT03395197 2026-04-07

TALAPRO-2

1,054 enrolled 21 charts 2 FDA

mCRPC

NCT04039607 2026-04-06

CheckMate 9DW

732 enrolled 3 FDA

Carcinoma, Hepatocellular

NCT04971226 2026-04-06

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

405 enrolled 18 charts 3 FDA

MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 5 FDA

Breast Neoplasms

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 3 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

415 enrolled 3 FDA

Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT04656652 2026-03-24

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

605 enrolled 14 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 3 FDA

Prostatic Neoplasms

NCT04924608 2026-03-23

KOMET

145 enrolled 17 charts 3 FDA

CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03298451 2026-03-20

HIMALAYA

1,324 enrolled 31 charts 2 FDA

Carcinoma, Hepatocellular

NCT05059262 2026-03-20

MOTION

123 enrolled 19 charts 3 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT03875235 2026-03-19

TOPAZ-1

810 enrolled 24 charts 2 FDA

Biliary Tract Neoplasms

NCT04211337 2026-03-19

LIBRETTO-531

291 enrolled 16 charts 3 FDA

Carcinoma, Medullary

NCT02166463 2026-03-17

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT04404283 2026-03-17

ECHELON-3

238 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 3 FDA

Gynecologic

Ovarian Neoplasms

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 3 FDA

Small Cell Lung Carcinoma

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05116189 2026-03-09

KEYNOTE-B96

643 enrolled 17 charts 3 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 2 FDA

Dermatologic

Melanoma

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 3 FDA

Breast Neoplasms

NCT03521154 2026-02-27

LAURA

216 enrolled 25 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

1,157 enrolled 3 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

635 enrolled 3 FDA

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02032823 2026-02-17

OlympiA

1,836 enrolled 20 charts 2 FDA

Breast Neoplasms

NCT03504397 2026-02-13

Spotlight

565 enrolled 63 charts 3 FDA

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 2 FDA

Multiple Myeloma

NCT02970318 2026-02-06

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

310 enrolled 18 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05198934 2026-02-06

CodeBreak300

160 enrolled 3 FDA

Colorectal Neoplasms

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 2 FDA